They should sell off the diagnostics business, especially the DxN program. Dick Creag*r isn't going to be able to launch this year, and won't be able to launch till at least 2nd quarter next year. (And this after they promised launched Q4 of 2011!!) And they are planning to launch with CMV?!?! A real big ticket assay, LOL! That and they can't seem to finish start verification testing of HBV, HCV, HIV. Danaher, would make sense for them to sell off this $800 million R&D hole.
↧